Chronic ulcerative stomatitis: case series of an under‐recognized entity

Journal of Cutaneous Pathology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2NwKpWk

Two‐phase delivery using a horse oil and adenosine‐loaded dissolving microneedle patch for skin barrier restoration, moisturization, and wrinkle improvement

Journal of Cosmetic Dermatology, EarlyView.


https://ift.tt/2wnYYow

The implementation of the consensus on the management of Helicobacter pylori and barriers to consensus

Helicobacter, EarlyView.


https://ift.tt/2on4OlL

Postsynaptic GluR2 Involved in Amelioration of Aβ-Induced Memory Dysfunction by KAIXIN-San Through Rescuing Hippocampal LTP in Mice

Rejuvenation Research, Ahead of Print.


https://ift.tt/2Pjs8w3

Three-Dimensional Coprinting of Liquid Metals for Directly Fabricating Stretchable Electronics

3D Printing and Additive Manufacturing, Ahead of Print.


https://ift.tt/2Nt8YDj

A case of cutaneous lymphoid hyperplasia after hyaluronic acid filler injection and fat grafting

Australasian Journal of Dermatology, EarlyView.


https://ift.tt/2Pkw0x4

Assessment of NETest Clinical Utility in a U.S. Registry‐Based Study

AbstractBackground.The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancers. We evaluated a blood‐based multigene assay for management of neuroendocrine tumors (NETs) in a real‐world study (U.S. registry NCT02270567). Diagnostic accuracy and relationship to clinical disease status in two cohorts (treated and watch‐and‐wait) were evaluated.Materials and Methods.Patients with NETs (n = 100) were followed for 6–12 months. Patients' primary tumors were gastroenteropancreatic (68%), lung 20%, and of unknown origin (12%). Characteristics included well‐differentiated, low‐grade tumors (97%), stage IV disease (96%); treatment with surgery (70%); and drug treatment (56%). NETest was measured at each visit and disease status determined by RECIST. Scores categorized as low (NETest 14%–40%) or high (≥80%) defined disease as stable or progressive. Multivariate analyses determined the strength of the association with progression‐free survival (PFS).Results.NETest diagnostic accuracy was 96% and concordant (95%) with image‐demonstrable disease. Scores were reproducible (97%) and concordant with clinical status (98%). The NETest was the only feature linked to PFS (odds ratio, 6.1; p < .0001). High NETest correlated with progressive disease (81%; median PFS, 6 months), and low NETest correlated with stable disease (87%; median PFS, not reached). In the watch‐and‐wait cohort, low NETest was concordant with stable disease in 100% of patients, and high NETest was associated with management changes in 83% of patients. In the treated cohort, all low NETest patients (100%) remained stable. A high NETest was linked to intervention and treatment stabilization (100%). Use of NETest was associated with reduced imaging (biannual to annual) in 36%–38% of patients.Conclusion.Blood NETest is an accurate diagnostic and can be of use in monitoring disease status and facilitating management change in both watch‐and‐wait and treatment cohorts.Implications for Practice.A circulating multigene molecular biomarker to guide neuroendocrine tumor (NET) management has been developed because current biomarkers have limited clinical utility. NETest is diagnostic (96%) and in real time defines the disease status (>95%) as stable or progressive. It is >90% effective in guiding treatment decisions in conjunction with diagnostic imaging. Monitoring was effective in watch‐and‐wait or treatment groups. Low levels supported no management change and reduced the need for imaging. High levels indicated the need for management intervention. Real‐time liquid biopsy assessment of NETs has clinical utility and can contribute additional value to patient management strategies and outcomes.

https://ift.tt/2wsF1wJ

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study

AbstractLessons Learned. The findings of this prospective, single‐arm, phase II study showed that neoadjuvant erlotinib was well tolerated and might improve the radical resection rate in patients with stage IIIA‐N2 epidermal growth factor receptor mutation‐positive non‐small cell lung cancer (NSCLC).Erlotinib shows promise as a neoadjuvant therapy option in this patient population.Next‐generation sequencing may be useful for predicting outcomes with preoperative tyrosine kinase inhibitors (TKIs) in patients with NSCLC.Large‐scale randomized controlled trials investigating the role of TKIs in perioperative therapy, combining neoadjuvant and adjuvant treatments to enhance personalized therapy for patients in this precision medicine era, are warranted.Background.Information on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as neoadjuvant therapy in non‐small cell lung cancer (NSCLC) is scarce. We evaluated whether neoadjuvant erlotinib improves operability and survival in patients with stage IIIA‐N2 EGFR mutation‐positive NSCLC.Methods.We conducted a prospective, single‐arm, phase II study. Patients received erlotinib 150 mg per day for 56 days in the neoadjuvant period. The primary endpoint was the radical resection rate.Results.Nineteen patients were included in the final analysis. After erlotinib treatment, 14 patients underwent surgery. The radical resection rate was 68.4% (13/19) with a 21.1% (4/19) rate of pathological downstaging. The objective response rate was 42.1%; 89.5% (17/19) of patients achieved disease control, with a 10.3‐month median disease‐free survival among patients who underwent surgery. Among all 19 patients who received neoadjuvant therapy, median progression‐free survival (PFS) and overall survival were 11.2 and 51.6 months, respectively. Adverse events (AEs) occurred in 36.8% (7/19) of patients, with the most common AE being rash (26.3%); 15.8% experienced grade 3/4 AEs. Quality of life (QoL) improvements were observed after treatment with erlotinib for almost all QoL assessments. Effects of TP53 mutation on prognosis were evaluated in eight patients with adequate tissue samples. Next‐generation sequencing revealed that most patients had a TP53 gene mutation (7/8) in addition to an EGFR mutation. No TP53 mutation, or very low abundance, was associated with longer PFS (36 and 38 months, respectively), whereas high abundance was associated with short PFS (8 months).Conclusion.Neoadjuvant erlotinib was well tolerated and may improve the radical resection rate in this patient population. Next‐generation sequencing may predict outcomes with preoperative TKIs.

https://ift.tt/2Pgwww0

Antitumor Effect of Nivolumab on Subsequent Chemotherapy for Platinum‐Resistant Ovarian Cancer

AbstractPlatinum‐resistant recurrent ovarian cancer is generally refractory to chemotherapy. Programmed cell death‐1 (PD‐1) signaling is a new target for antitumor therapy. The anti‐PD‐1 antibody nivolumab had a 10% durable complete response rate in our phase II clinical trial. However, how nivolumab affects sensitivity to subsequent chemotherapy remains unclear. We encountered several cases of unexpected antitumor response among patients who underwent palliative chemotherapy in the follow‐up study of our phase II nivolumab trial (UMIN000005714). Several agents had an unexpected antitumor response in patients who were resistant or refractory to standard chemotherapeutic agents. In one patient, both pegylated liposomal doxorubicin (PLD) and nedaplatin (CDGP) resulted in partial response. In another patient, PLD and CDGP resulted in partial response and stable disease, respectively. These two patients remained alive on the cutoff date. These two cases raise the possibility that nivolumab might improve sensitivity to adequate chemotherapy for ovarian cancer.

https://ift.tt/2BV9ZD3

The Current and Evolving Landscape of First‐Line Treatments for Advanced Renal Cell Carcinoma

AbstractAgents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune checkpoint receptor programmed death 1 (PD‐1) signaling pathway have improved clinical outcomes for patients with advanced renal cell carcinoma (RCC). The VEGFR tyrosine kinase inhibitors (TKIs) pazopanib and sunitinib are FDA‐approved first‐line treatment options for advanced RCC; however, other treatment options in this setting are available, including the recently approved combination of nivolumab (anti‐PD‐1) and ipilimumab (anti‐cytotoxic T‐lymphocyte‐associated protein‐4 [CTLA‐4]) for patients with intermediate or poor risk. Unfortunately, treatment guideline recommendations provide little guidance to aid first‐line treatment choice. In addition, several ongoing randomized phase III trials of investigational first‐line regimens may complicate the RCC treatment paradigm if these agents gain approval. This article reviews clinical trial and real‐world evidence for currently approved and investigational first‐line treatment regimens for advanced RCC and provides clinical evidence to aid first‐line treatment selection.Implications for Practice.Vascular endothelial growth factor receptor tyrosine kinase inhibitors are approved by the U.S. Food and Drug Administration as first‐line treatment options for advanced renal cell carcinoma; however, the treatment paradigm is rapidly evolving. The combination of nivolumab plus ipilimumab was recently approved for intermediate‐ and poor‐risk patients, and other combination strategies and novel first‐line agents will likely be introduced soon.

https://ift.tt/2PPCvbV

Dietary Intervention with Oatmeal in Patients with uncontrolled Type 2 Diabetes Mellitus – A Crossover Study

Exp Clin Endocrinol Diabetes
DOI: 10.1055/a-0677-6068

Background In a pilot study, we evaluated the efficacy of two days of oatmeal on insulin resistance and glucose metabolism and found a marked decrease of insulin requirements. The most important shortcoming of that study was that the interventions were not isocaloric (diabetes adapted diet: 1500 kcal/d vs. oatmeal 1100 kcal/d). To address these drawbacks we designed the OatMeal And Insulin Resistance (OMA-IR) study. Methods The study was a randomized, open label crossover dietary intervention study with consecutive inclusion of 15 patients with uncontrolled type 2 diabetes. The intervention comprised two days of oatmeal on days 3 and 4 of a 5 days hospital stay. During the control period, patients received a diabetes mellitus adapted diet only. The primary endpoint was the daily insulin requirement and glycemic control. Results Upon oatmeal treatment, the required insulin dose could be significantly reduced on the third and fourth day as compared to the second day of inpatient stay (82.0±30.3 and 69.9±29.9IU versus 112±36.2IU;P<0.001). During control treatment, insulin requirement did not change. There were no significant differences in the changes of mean blood glucose or fasting glucose between both treatments. HbA1c was lower four weeks after the oatmeal intervention. Conclusion In this crossover study, two days of oatmeal intervention allowed a highly significant reduction of required daily insulin doses while maintaining adequate metabolic control as compared to a diabetes adapted diet only. The beneficial effects of the intervention might last for several weeks as shown by the lower HbA1c four weeks after the intervention.
[...]

© Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Abstract  |  Full text

https://ift.tt/2PgIFkk

Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study

Exp Clin Endocrinol Diabetes
DOI: 10.1055/a-0636-3961

Purpose To assess quality of life, glycemic control, and safety/tolerability associated with liraglutide versus insulin initiation in patients with type 2 diabetes in Germany. Methods Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks. The primary objective was to evaluate Audit of Diabetes-Dependent Quality of Life (ADDQoL) scores. Results At baseline, the liraglutide group was younger and had shorter type 2 diabetes duration, lower glycated hemoglobin (HbA1c), higher body mass index, and a lower prevalence of certain diabetes-related complications than the insulin group (all p<0.05). ADDQoL average weighted impact scores improved numerically in both groups from baseline to 52 weeks (mean difference [95% confidence interval], liraglutide vs. insulin: 0.159 [−0.023;0.340]; not significant). Changes in general wellbeing and five ADDQoL domains significantly favored liraglutide (remaining 14 domains, not significant). HbA1c reductions were greater with insulin than liraglutide (−2.0% vs. −1.2%; p<0.01); however, mean HbA1c after 52 weeks was 7.2% in both groups. Compared with insulin, liraglutide significantly decreased body mass index (−1.54 kg/m2 vs. +0.27 kg/m2; p<0.001), systolic blood pressure (−5.03 mmHg vs. −1.03 mmHg; p<0.01) and non-severe hypoglycemia (0.85% vs. 4.55% at 52 weeks; p<0.01). Adverse drug reactions were reported for<3% of patients in both groups. Conclusions Liraglutide improved certain ADDQoL components and reduced body mass index, systolic blood pressure, and non-severe hypoglycemia versus insulin. Both treatments improved glycemic control.
[...]

© Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Abstract  |  Full text

https://ift.tt/2PNm5kt

The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients

Exp Clin Endocrinol Diabetes
DOI: 10.1055/a-0684-9601

Objectives Impaired glucose metabolism represents one the most important cardiovascular risk factors, with steeply raising prevalence in overall population. We aimed to compare mortality risk of impaired fasting glycaemia (IFG) and overt diabetes mellitus (DM) in patients with coronary heart disease (CHD). Study design prospective cohort study Methods A total of 1685 patients, 6–24 months after myocardial infarction and/or coronary revascularization at baseline, were followed in a prospective cohort study. Overt DM was defined as fasting glucose ≥ 7 mmol/L and/or use of antidiabetic treatment, while IFG as fasting glucose 5.6–6.99 mmol/L, but no antidiabetic medication. The main outcomes were total and cardiovascular mortality during 5 years of follow-up. Results During follow-up of 1826 days, 172 patients (10.2%) deceased, and of them 122 (7.2%) from a cardiovascular cause. Both exposures, overt DM (n=623, 37.0% of the whole sample) and IFG (n=436, 25.9%) were associated with an independent increase of 5-year total mortality, compared to normoglycemic subjects [fully adjusted hazard risk ratio (HRR) 1.63 (95%CI: 1.01–2.61)]; p=0.043 and 2.25 (95%CI: 1.45–3.50); p<0.0001, respectively]. In contrast, comparing both glucose disorders one with each other, no significant differences were found for total mortality [HRR 0.82 (0.53–1.28); p=0.33]. Taking 5-years cardiovascular mortality as outcome, similar pattern was observed [HRR 1.96 (95%CI: 1.06–3.63) and 3.84 (95%CI: 2.19–6.73) for overt DM and IFG, respectively, with HRR 0.63 (95%CI: 0.37–1.07) for comparison of both disorders]. Conclusions Impaired fasting glycaemia adversely increases mortality of CHD patients in the same extent as overt DM.
[...]

© Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Abstract  |  Full text

https://ift.tt/2PhwTpM

Characteristic features of neck skin aging in Chinese women

Journal of Cosmetic Dermatology, EarlyView.


https://ift.tt/2BZxI4Y

Optical coherence tomography (OCT) findings in obstructive sleep apnea

We have read the article by Mentek et al., however, we believe some discussion would be of benefit.1 The authors describe vascular disorders of the retina and the optic nerve in patients affected by obstructive sleep apnea (OSA). When reviewing results of eye tests of this disorder, it is necessary to mention that OSA itself presents alterations in particular ophthalmic examinations.

https://ift.tt/2wzFpc2

Determining the likelihood that fatigue was present in a road accident: A theoretical review and suggested accident taxonomy

Estimates in developed countries of the extent to which fatigue contributes to road accidents range from as low as 5% to as high as 50% of all accidents. Compared with other causes of road accidents (e.g. speeding, drink-driving), the variability in these estimates is exceptionally high and may be indicative of the difficulty in determining the likelihood of fatigue as a cause of road accidents.This review compares differences in the way road accidents are classified as fatigue-related (or not) by expert panels and road safety regulators, highlighting conflicting conceptual approaches, lack of consistency, and the poor psychometric qualities of classification rules used across jurisdictions.

https://ift.tt/2ojsFCN

Biofeedback Rehabilitation to Improve Speaking and Eating in Public

Condition:   Oral Cavity Squamous Cell Carcinoma
Intervention:   Device: Electropalatography Biofeedback Training
Sponsors:   Douglas Chepeha;   University Health Network, Toronto
Not yet recruiting

https://ift.tt/2MGvfS9

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Ramucirumab;   Drug: Pembrolizumab;   Other: EORTC QLQ-30;   Other: FACT H&N;   Procedure: Peripheral blood
Sponsors:   Washington University School of Medicine;   Eli Lilly and Company
Not yet recruiting

https://ift.tt/2NuYeVd

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Conditions:   Cervical Cancer;   Gastric Cancer (Including Stomach and Gastroesophageal Junction);   Esophageal Cancer;   Hepatocellular Carcinoma;   Melanoma (Uveal Melanoma Excluded);   Merkel Cell Carcinoma;   Mesothelioma;   Microsatellite Instability (MSI)-High/ Deficient Mismatch Repair (dMMR) Tumors;   Non-small Cell Lung Cancer (NSCLC);   Ovarian Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Small Cell Lung Cancer;   Renal Cell Carcinoma (RCC);   Triple-negative Breast Cancer;   Urothelial Carcinoma
Intervention:   Drug: INCAGN02390
Sponsor:   Incyte Corporation
Not yet recruiting

https://ift.tt/2MAwPVs

Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study

Condition:   Head and Neck Cancer
Interventions:   Device: PTSD Coach;   Behavioral: Game application
Sponsors:   Jewish General Hospital;   Canadian Institutes of Health Research (CIHR)
Not yet recruiting

https://ift.tt/2NvziNk

Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

Conditions:   HNSCC;   DNA Damage;   DNA Double Strand Break
Interventions:   Other: Biomarker Research;   Drug: Nivolumab
Sponsor:   Attikon Hospital
Recruiting

https://ift.tt/2MFjPxJ

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Conditions:   Recurrent Squamous Cell Carcinoma of the Head or Neck;   Platinum- and Cetuximab-Refractory Squamous Cell Carcinoma of the Head or Neck;   Metastatic Squamous Cell Carcinoma of the Head or Neck;   Squamous Cell Carcinoma
Interventions:   Drug: Nivolumab;   Drug: Afatinib
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Comprehensive Cancer Network;   Boehringer Ingelheim
Not yet recruiting

https://ift.tt/2NvXn6D

Defining and validating a Body Skin Discomfort Index (BSDI)

International Journal of Cosmetic Science, Volume 0, Issue ja, -Not available-.


https://ift.tt/2N79EBL

Treatment outcomes in pediatric differentiated thyroid carcinoma

Journal Name: Journal of Pediatric Endocrinology and Metabolism
Issue: Ahead of print


https://ift.tt/2wow9bt

Are breast milk adipokines affected by maternal dietary factors?

Journal Name: Journal of Pediatric Endocrinology and Metabolism
Issue: Ahead of print


https://ift.tt/2LAu0hG

Ultrasonographic evaluation of masseter muscle thickness in patients with disk displacement with reduction

Abstract

Objectives

This study was performed to ultrasonographically assess the masseter muscle thicknesses of individuals with disk displacement with reduction.

Methods

The thickness of the masseter muscle in 100 patients (28 male, 72 female; average age 34 years) who presented with one-sided temporomandibular joint pain and a clicking sound and were diagnosed with disk displacement with reduction was measured in relaxation and at maximum contraction using ultrasonography.

Results

In the contracted position, the difference in the masseter muscle thickness between the healthy side and the side with disk displacement with reduction was statistically significant (p < 0.05). However, no statistically significant difference was found between the two sides in the relaxed position.

Conclusions

Obvious ultrasonographic changes of the masseter muscle were found in patients with temporomandibular disk displacement with reduction, and these changes might be related to unilateral chewing. Individuals with anterior disc displacement probably chew unilaterally because of pain and clicking.

https://ift.tt/2wpHckZ

The association of garlic with Helicobacter pylori infection and gastric cancer risk: A systematic review and meta‐analysis

Helicobacter, EarlyView.


https://ift.tt/2wql1uI

Real‐time PCR for Helicobacter pylori diagnosis. The best tools available

Helicobacter, EarlyView.


https://ift.tt/2wuCRvQ

Minoxidil in the treatment of androgenetic alopecia

Dermatologic Therapy, EarlyView.


https://ift.tt/2N0K8On

Functional nutrition as integrated approach in vitiligo management

Dermatologic Therapy, EarlyView.


https://ift.tt/2BXqaQ5

Glycolic acid cream for treatment of molluscum contagiosum

Dermatologic Therapy, EarlyView.


https://ift.tt/2MVDmte

Is carboxytherapy a good alternative method in the removal of various skin defects?

Dermatologic Therapy, EarlyView.


https://ift.tt/2BZfj8y

Surgical excision and mucosal advancement flap: Treatment for refractory lichen planus of the lip

Dermatologic Therapy, EarlyView.


https://ift.tt/2PNONBD